WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and ...

In a prostate cancer mouse model (22Rv1 xenografts), the combination of 225 Ac-YS5 (0.12 µCi) + YS5-MMAE (1.8 mg/kg) was associated with the most significant reduction in tumor volume (green curves in ...

Two new drugs for Alzheimer’s have been rejected for use on the NHS. They slow progression of the disease, but they can have ...

Phase 1 data for Spyre Therapeutics, Inc.'s SPY002 & SPY072 show promise in autoimmune treatments. Advancing to Phase 2 ...

Department of Chemistry, Hunter College of the City University of New York, New York, New York 10028, United States Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York ...

EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumor-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. The updated findings showed promising efficacy data ...

1Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, Canada. Search for other works by this author on: 1Department of Medical Imaging, College of Medicine, ...

Antibody-drug combination outperforms standard treatment of advanced triple-negative breast cancer by Dana-Farber Cancer Institute edited by Gaby Clark , reviewed by Andrew Zinin ...

Objective Anti-NMDA receptor encephalitis is the most prevalent autoimmune encephalitis having characteristic clinical features with autoantibodies against tetrameric transmembrane channels composed ...

which shows the drug developer’s confidence in this drug. PM1022 is a bispecific antibody targeting PD-L1 and TIGIT, with VHH targeting PD-L1 fused to the C-terminus of the anti-TIGIT antibody. The ...

Navigator is also advancing NAV-242, a next-generation, engineered anti-OX40L/TNFα antibody, with half-life-extension, which has the potential for optimized exposure and dosing profile to provide a ...